A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Effectiveness and Safety of ZP5-9676 for the Treatment of Hookworm (Ancylostoma Duodenale and Necator Americanus), Ascaris Lumbricoides, and Trichuris Trichiura in Pediatric and Adult Participants
Latest Information Update: 13 Oct 2025
At a glance
- Drugs ZP5 9676 (Primary)
- Indications Helminthiasis
- Focus Registrational; Therapeutic Use
- Sponsors Zero Point Five Therapeutics
Most Recent Events
- 25 Sep 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 25 Sep 2025 Planned primary completion date changed from 1 Dec 2025 to 1 May 2026.
- 25 Sep 2025 Status changed from not yet recruiting to recruiting.